Latest News
Arma Partners has acted as the exclusive financial advisor to Bregal Unternehmerkapital on the majority recapitalisation of its portfolio company proALPHA Business Solutions by Intermediate Capital Group (ICG).
Bregal will remain involved in the further development of proALPHA through a continuing interest alongside ICG, strengthening proALPHA’s shareholder structure with long-term capital resources for growth investments.
Founded in 1992, proALPHA is one of the largest providers of Enterprise Resource Planning (ERP) solutions for medium-sized manufacturing and trading companies in the DACH region. With more than 900 employees worldwide, the company serves approximately 1,800 small and mid-sized customers (SMEs) driving digital
IMV Europe Limited, part of Osaka based IMV Corporation which manufactures noise and vibration test equipment and has turnover of JPY10.3 billion, has simultaneously acquired two businesses; GBP2.1 million turnover Vibratech, and GBP2.4 million turnover CVMSL with advice from Martin Kennedy and Jeff Barber of BTG Corporate Finance in Manchester.
Listed on the JASDAQ securities market, IMV Corporation is the world’s leading supplier of high reliability vibration test and measurement systems. IMV Europe’s facilities include a technical centre at Letchworth from where it develops cutting edge test and measurement solutions.
Based in Hertforshire, Vibratech is a specialist in the
Epidarex Capital (Epidarex), an early stage life science venture capital firm, has sold portfolio company Confluence Life Sciences to Aclaris Therapeutics, for a total deal value of up to USD100 million in up-front and milestone payments.
The Confluence investors are also eligible to receive future payments on royalties on drug product sales.
Confluence was established in 2010 by an experienced team of former Pfizer executives and researchers in St. Louis, MO. The company’s focus is the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer. Its assets include: CDD-450, a novel MK-2 pathway inhibitor;
Palatine Private Equity has invested in its Midlands team with the appointment of Tom Hustler as Investment Manager.
Hustler joins from The Royal Bank of Scotland where he worked as an Associate Director in the Structured Finance team. During his time there, Tom worked on a range of large corporate deals and private equity transactions. In his role, he was responsible for originating, structuring, evaluating and completing a range of event-led transactions including M&A, recapitalisations and MBO’s.
Having trained as an accountant, he started his career at KPMG as an Audit Manager for a number of Midlands-based clients of
One of the UK’s fastest-growing housing developers has announced a turnover increase of more than 35 per cent in its annual results.
Westleigh Partnerships, which is backed by Private equity firm Palatine, specialises in building affordable homes for housing associations and local authorities, as well as high quality new homes for the local market, turned over GBP128.6m in the year to March 31 2017, up from GBP95.1m the previous year.
Profit before tax jumped by more than 75 per cent, up to GBP10.9 million from GBP6.1 million. The firm also announced a sizeable increase in its land reserves, with
North American mergers and acquisitions specialist Robbinex is expanding its service offerings with the launch of COSATA in response to a changing M&A marketplace.
COSATA stands for Comprehensive Strategic Analysis of Transition Alternatives. When a business owner is interested in selling or transitioning their business, the COSATA approach takes them beyond a simple valuation of their current business to identify changes that will enhance its value, and considers alternatives to selling.
“We analyse hundreds of potential buyers for every business we help bring to market, and we’ve identified there isn’t a scarcity of buyers, but a rather a general
SK Capital, a private investment firm focused on the specialty materials, chemicals and pharmaceuticals sectors, is to to acquire Perrigo API, Perrigo Company’s active pharmaceutical ingredients (API) business.
As part of the transaction, the parties have agreed to enter into a long-term supply agreement for Perrigo API to supply multiple existing commercial and pipeline APIs to Perrigo. The transaction is expected to close during Q4 2017, before which a new trade name will be selected and announced for the Business.
Perrigo API is a leading developer and manufacturer of generic APIs and finished dose forms (“FDF”) with operations primarily
NSR Invest and LendingRobot have merged to create a new combined independent advisory platform for alternative lending. Lend Core LLC, the parent company of NSR Invest, acquired Algorithmic, and all its assets, including the LendingRobot website and technology.
The combination brings together two highly complementary companies, each with an excellent reputation in the alternative, marketplace lending industry, also called peer lending. The joint team will combine its knowledge in the industry, investment algorithms, machine learning and blockchain technologies with the goal of providing steady investment returns to more than 8000 clients.
The websites, operating, and trading systems of NSRinvest.com
Stonehenge Growth Capital has made an investment in PosiGen that will enable the solar company to expand operations in Connecticut and provide clean energy technology to hundreds of low- to moderate-income Connecticut households.
Stonehenge Growth Capital, a subsidiary of Stonehenge Capital Company, made the USD5 million investment through the Invest CT program. Solar panels installed by PosiGen have already reduced the energy cost burden faced by over 10,000 families across four states, including Connecticut, New York, Louisiana and Florida. Stonehenge’s investment will allow PosiGen to provide an additional 750 rooftop solar panel systems to further reduce Connecticut households’ energy costs.
Sverica Capital Management (Sverica) has acquired a majority interest in Women’s Health USA (WHUSA). The investment is Sverica’s fourth investment from Fund IV.
Based in Avon, Connecticut, WHUSA is a national physician practice management organisation focused on women’s health, including OBGYN and In Vitro Fertilisation. WHUSA provides physician practices with a full suite of practice management solutions including revenue cycle management, payor contracting, EMR & technology management, financial & accounting, risk management, and others. WHUSA’s unique model creates true partnerships, which allow affiliate physician groups to retain their identity and autonomy while providing best-in-class operational management, capital for growth, and
Special Reports
Featured
Events
12 November, 2026 – 8:00 am
12 November, 2026 – 5:00 pm
